Hana says anti-cancer drug gets fast-track designation

Aug 22 (Reuters) - Biopharmaceutical company Hana Biosciences (HNAB.O) said U.S. health regulators granted fast-track designation to its anti-cancer drug, Marqibo.

The company said Marqibo received the status for the treatment of adults with Philadelphia chromosome negative acute lymphoblastic leukemia in second relapse, or for those who have failed two lines of prior therapy. Marqibo was also granted orphan drug designation by the Food and Drug Administration for the treatment of adult acute lymphoblastic leukemia earlier this year, Hana added.

(Reporting by Esha Dey in Bangalore)

((Editing by Anil Kumar; Reuters Messaging: esha.dey.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: HANA FASTTRACK/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2608